Seattle Genetics

February 5, 2012

Baker’s Dozen Trying to Beat the Odds in Pancreatic Cancer

October 23, 2011 By MD Becker Partners 1 Comment

Pancreatic Cancer Image

November marks Pancreatic Cancer Awareness Month – a baker’s dozen are trying to beat the odds in treating the disease.

Filed Under: Articles Tagged With: 2011 Nobel Prize in Medicine, AAPL, Abraxane, Aduro BioTech, Afinitor, Algenpantucel-L, American Cancer Society, AMG 479, Amgen, AMGN, Apple, Astellas Pharma, Bayer Schering Pharma, CELG, Celgene Corporation, Clovis Oncology, CO-101, CRS-207, Eli Lilly, erlotinib, everolimus, gemcitabine, Gemzar, GlobeImmune, hENT1 protein, IMMU, Immunomedics, INFI, Infinity Pharma, IPI-926, islet cell tumors, LLY, neuroendocrine tumors of pancreatic origin, NewLink Genetics Corporation, Novartis, Novartis AG, Oncolytics Biotech, ONCY, pancreatic cancer, pancreatic NET, Patrick Swayze, Ralph Steinman, Seattle Genetics, Steve Jobs, Tarceva, TH-302, THLD, Threshold Pharmaceuticals

Past Pitfalls and Potential Promise for Pancreatic Cancer

October 25, 2010 By MD Becker Partners Leave a Comment

pancreatic_slide

Next month [November] marks Pancreatic Cancer Awareness Month. Visibility for the disease is already on the rise due to recent celebrity victims, including Apple’s Steve Jobs and Hollywood actor Patrick Swayze. According to the American Cancer Society, pancreatic cancer is a devastating disease with the worst mortality rate and an overall 5-year survival rate lower [...]

Filed Under: Articles Tagged With: 90Y-hPAM4, AAPL, Abraxane, Abraxis BioScience, Afinitor, ALPMY.PK, AMG 479, Amgen, AMGN, Aphton Corp, Apple, ASG-5ME, Astellas Pharma, Bayer Schering Pharma AG, BioSante Pharmaceuticals, BPAX, CA19-9, CDX-1307, CELG, Celgene Corporation, Celldex Therapeutics, CLDX, Clivatuzumab tetraxetan, Eli Lilly, ensituximab, everolimus, gemcitabine, Gemzar, GenVec, GI-4000, GlobeImmune, GNVC, GVAX, ImClone Systems, IMMU, Immunomedics, INFI, Infinity Pharma, IPI-926, LLY, Neogenix Oncology, Neuroendocrine tumors, Novartis, NPC-1C, NVS, Oncolytics Biotech, ONCY, paclitaxel, pancreatic cancer, Patrick Swayze, PCI-27483, PCYC, PFE, Pfizer, Pharmacyclics, PTK787, Regeneron Pharmaceuticals, REGN, Roche Holdings, Sanofi-Aventis, SciClone Pharmaceuticals, SCLN, Seattle Genetics, SGEN, SNY, Steve Jobs, SuperGen, SUPG, TH-302, Therion Biologics, THLD, Threshold Pharmaceuticals, Vatalanib, ZK-222584)

Investment Opportunities with Five Frontline Therapies for AML

September 6, 2010 By MD Becker Partners 2 Comments

473462-small

Acute myelogenous leukemia [AML] is a fast-growing cancer of the blood and bone marrow. Unformed cells called myeloblasts, or “blasts,” reside in the bone marrow and normally become a particular kind of cell – a white blood cell, red blood cell, or platelet. In AML, abnormal blasts produce white blood cells that do not function [...]

Filed Under: Articles Tagged With: AC220, Acute myelogenous leukemia, Ambit Biosciences, AML, AraC, Astellas Pharma, azacitidine, blasts, CD33 receptor, CELG, Celgene, CEPH, Cephalon, clofarabine, Clolar, CYCC, Cyclacel Pharmaceuticals, cytarabine, Dacogen, daunorubicin, decitabine, Eisai, ESALF, farnesyltransferase inhibitors, FDA, Food and Drug Administration, gemtuzumab ozogamicin, GENZ, Genzyme Corporation, hypomethylating agents, idarubicin, JNJ, Johnson & Johnson, laromustine, lestaurtinib, lintuzumab, monoclonal antibodies, Mylotarg, nucleoside analogs, Onrigin, PFE, Pfizer, Sanofi-Aventis, sapacitabine, Seattle Genetics, SGEN, SNSS, SNY, SPA, special protocol assessment, sunesis, SuperGen, SUPG, tipifarnib, topoisomerase II inhibitors, Vidaza, Vion Pharmaceuticals, voreloxin, vosaroxin, Zarnestra

Monoclonal Antibody Companies Command Premiums

July 11, 2010 By MD Becker Partners Leave a Comment

Monoclonal antibody image from MD Becker Partners

Monoclonal antibodies, which have been approved for immunological, anti-infective, ophthalmic, cancer and other categories, represent one of the most successful therapeutic drug classes. Ten monoclonal antibodies have been approved for cancer therapy alone, including three blockbuster products sold by the Roche Group (RHHBY) – Avastin® [bevacizumab], Rituxan® [rituximab], and Herceptin® [trastuzumab] that collectively represented nearly [...]

Filed Under: Articles Tagged With: Abbott, Abgenix, ABT, adalimumab, Agensys, Alexion Pharmaceuticals, ALXN, Astellas Pharma, AstraZeneca, Avastin, Bayer Schering Pharma AG, BAYRY.PK, bevacizumab, biosimilars, BMY, Bristol-Myers Squibb, Cambridge Antibody Tech, CEPH, Cephalon, Ception Therapeutics, cetuximab, Domantis, Eli Lilly & Co, Erbitux, erlotinib, Facet Biotech, FDA, GEN.CO, Genmab A/S, GENZ, Genzyme, Herceptin, HGSI, Human Genome Sciences, Humira, ImClone Systems, IMGN, IMMU, ImmunoGen, Immunomedics, Inc., infliximab, KaloBios Pharmaceuticals, LLY, mAbs, MacroGenics, MedImmune, Micromet, MITI, monoclonal antibodies, MORG.DE, Morphosys AG, Morphotek, NASDAQ Biotechnology Index, NBI, NeuTec Pharma plc, OncoMed Pharmaceuticals, OSI Pharmaceuticals, PFE, Pfizer, Regeneron, REGN, Remicade, RHHBY, Rinat Neuroscience Corp, Rituxan, rituximab, roche, sanofi-aventis Group, Seattle Genetics, SGEN, SNY, Tarceva, trastuzumab, Tufts Center for the Study of Drug Development, XOMA

Buyout Buzz at ASH Hematology Confab

December 7, 2009 By MD Becker Partners 1 Comment

473462-small

Scientific and medical advances weren’t the only topic of discussion at the 51st American Society of Hematology [ASH] Annual Meeting that began over the weekend in New Orleans, LA, as merger and acquisition activity took center stage. Early this morning, Celgene Corporation (CELG) announced the acquisition of privately-held Gloucester Pharmaceuticals for $340 million in cash [...]

Filed Under: Articles Tagged With: Allos Therapeutics, ALTH, brentuximab vedotin, CELG, Celgene, CYCC, Cyclacel Pharmaceuticals, Folotyn, Gloucester Pharmaceuticals, Istodax, peripheral T-cell lymphoma, pralatrexate, sapacitabine, Seattle Genetics, SGEN, ZIOP, ZIOPHARM Oncology